Cboe has submitted an application to the SEC for the approval of a new exchange-traded fund (ETF) linked to the INJ token of the Injective Protocol. This ETF offers investors a unique opportunity not only to track the token's price but also to earn income through staking.
What is the Canary Staked Injective ETF
The fund, known as the Canary Staked Injective ETF, is being put forward by investment firm Canary Capital Group LLC. If approved, the ETF would allow investors to gain exposure to Injective’s native token (INJ), not just through its market price, but also by earning extra income from staking.
Benefits of Staking for Investors
Staking means locking the tokens into the Injective blockchain to help keep the network running. By staking the tokens, the fund can earn rewards, and those rewards would be passed on to investors. Thus, instead of just tracking the token’s market price, this ETF provides an opportunity to earn additional income through staking.
Implications of the Application for the Crypto Market
The filing also highlights changes in the investment and regulatory landscape. In May 2025, the SEC released guidance stating that some types of staking may not count as securities offerings. This encouraged many firms to begin developing staking-based investment products. If approved, this ETF would become the third staking-enabled ETF in the United States, following the recent approval of staked Solana and Ethereum products.
Thus, Cboe's application for the INJ-linked ETF opens new avenues for investors, offering not only standard investment opportunities but also additional income through staking. This reflects the growing interest in innovative approaches in the crypto market.
